Taletrectinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Taletrectinib. Educational only — not medical advice.
Labeled uses
IBTROZI® (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration (2.1 )] .
Source: FDA labeling via NIH DailyMed (set 51ac8e52…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.